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DAS28-predictorsAbstract Aim of work: To assess the impact of rheumatoid arthritis (RA) on the health related
quality of life (QoL) of patients, using the 36-item short form (SF-36) and to study the inﬂuence
of different disease variables.
Patients and methods: Eighty-six RA patients were recruited from the Rheumatology and
Rehabilitation outpatient of Assiut University Hospital. Forty-three, age and sex matched subjects
were included as controls. The QoL was measured in all subjects using the SF-36 health survey.
Disease activity was assessed in RA patients by the disease activity score (DAS28).
Results: All domains of the SF36 were signiﬁcantly lower in the patients (p< 0.0001). Patients
with a lower educational level and those unemployed had signiﬁcantly lower SF36 components.
Those with a disease duration >5 years, positive rheumatoid factor and higher disease activity
had a signiﬁcantly lower SF36 physical component. Patients receiving hydroxychloroquine or pred-
nisolone had signiﬁcantly lower mental component. Signiﬁcant negative correlation of the SF36
physical and mental components was found with both disease duration (p= 0.01 and p< 00001
respectively) and DAS28 (p< 0.0001 for both). Rheumatoid factor negatively correlated with
the physical component (p< 0.0001). Regression analysis showed that disease duration was the
most profound predictor of both SF36 components (p< 0.0001).
Conclusion: The quality of life is impaired in Egyptian RA patients and disease duration was the
most signiﬁcant predictor. Routine assessment of the health-related QoL in those patients is recom-
mended to detect and monitor the impact of the disease and medications used on different aspects
of their quality of life.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Rheumatoid arthritis (RA) is an autoimmune disease that typ-
ically affects the small joints of the hands and feet, often sym-
metrically. It is usually presented with constant pain, stiffness,
progressive joint destruction and deformity with signiﬁcant
disability [1]. Impairment of the quality of life (QoL) has been
reported in RA [2]. The underlying pathogenic processes of
most rheumatic diseases start years before the clinical diagno-
sis is made and irreversible joint damage occurs, and as the
long-term morbidities decrease with prompt, responsible and
aggressive treatment with disease-modifying therapy; both
forming core challenges [3].
The QoL is now recognized as an important outcome vari-
able in patients with chronic diseases. The QoL goes beyond
the impairment/disability and handicap continuum by asking
what patients’ health status prevents them from doing and also
about their emotional response to these restrictions. It also
reﬂects the inﬂuences of the personal social and economic
resources that an individual has and the way in which these
interact with health status. Therefore, QoL could be deﬁned
as perception of people about life, values, goals, standards,
and interests [4].
In other studies on Egyptian patients with different rheu-
matic diseases as systemic lupus erythematosus [5,6], sys-
temic sclerosis [7], juvenile idiopathic arthritis [8],
ankylosing spondylitis [9], osteoarthritis [10], ﬁbromyalgia
syndrome [11], benign joint hypermobility syndrome [12]
functional impairment and poor QoL were reported. The
impaired functioning caused by RA can be debilitating, both
physically and mentally. Reduced health related QoL
(HRQoL) in RA patients is associated with increased use
of healthcare resources and with increased level of depres-
sion. In addition to bad effects on patients’ QoL and life
expectancy, RA has a considerable ﬁnancial impact on
patients’ family, health care payers, and society [1]. In other
studies on Egyptian RA patients, impaired QoL was
reported but using the health assessment questionnaire
(HAQ) measures [13–15].
Generic and disease speciﬁc QoL instruments have been
validated for assessment in RA. Disease-speciﬁc measures
have the advantage that they have been designed to pick
up health-related aspects particular to the speciﬁc disease.
On the other hand, the main advantages of generic measures
are their ability to detect changes in early disease [1], and the
possibility of comparing disability in RA with other diseases
[16]. Moreover, the Disease-speciﬁc instrument included to
measure functional limitations, the HAQ in RA was closely
correlated to the physical functioning dimension of the 36-
item short form (36-SF) health survey [17], therefore SF-36
is considered a valid instrument for measuring physical func-
tioning and comparing different aspects of HRQoL in
patients with RA.
As current treatment neither prevents nor cures RA, the
main management aim should be to reduce the impact of the
disease on patients’ lives by improving quality of life and
reducing disability. The present study aimed to assess the
impact of RA on HRQoL of patients using a generic instru-
ment, and study the inﬂuence of different disease variables
on HRQoL.2. Patients and methods
2.1. Patients
In this cross-sectional study, we enrolled 86 consecutive patients
(both male and female at a minimum age of 18 years) diagnosed
with RA, conﬁrmed by a rheumatologist based on the 2010
ACR/EULAR classiﬁcation criteria [18]. Patients were
recruited from those attended sequentially to the outpatient
clinic of Physical Medicine, Rheumatology and Rehabilitation
department, Assiut university Hospital, in the period between
January and July 2014. Exclusion criteria were bed ridden
patients and the presence of signiﬁcant co-morbidity, such as
malignancies or end stage organ failure. Pregnant ladies were
excluded. The study was approved by the Ethics Committee
onHumanResearch of AssiutUniversity. Verbal informed con-
sents were obtained from all participants. We enrolled 43
healthy age and sex matched volunteers as control.
2.2. Methods
A checklist containing questions on demographic data (age,
gender, formal education level, and work status) was com-
pleted by all subjects and was collected upon enrollment. All
patients performed laboratory investigations and underwent
a medical examination by a single rheumatologist who also
determined the disease duration and assessed the disease activ-
ity score in 28-joints (DAS-28) [19]. Patients were classiﬁed as
in remission (<2.6), low (P2.6 to <3.2), moderate (P3.2 to
65.1), and high (>5.1) disease activity. Extra-articular (EA)
manifestations were identiﬁed clinically and conﬁrmed using
investigations when indicated. Current medication history
was also collected. HRQoL was measured via the Medical
Outcomes Study 36-SF health survey [20]. SF-36 is a generic
multidimensional measure of HRQoL that contains eight sub-
scales representing physical functioning (PF), social function-
ing (SF), role limitations due to physical health problems
(RP), role limitations attributable to emotional problems
(RE), mental health (MH), vitality (VT), bodily pain (BP),
and general health perceptions (GH). Higher scores of each
subscale (which range from 0 to 100) indicate a better
HRQoL. The physical and mental components of the eight
scales are combined into physical (PCS) and mental (MCS)
component summary scale scores.
2.2.1. Statistical analysis
Statistical analysis of data was done by using the Statistical
Package of Social Science (SPSS) version 16 software.
Descriptive statistics were performed for all variables of the
study. Mann–Whitney U test was used to compare means of
demographic and clinical data between RA patients and the
control group. Kruskal–Wallis test was used to compare the
means of >2 independent variables as our data lack normal
distribution in mean values and had considerable inequality
in the number of patients per group. Spearman Correlation
was measured between different demographic, clinical vari-
ables and PCS or MCS score. Multiple linear regression anal-
ysis using enter method was performed for QoL predictor
determination. Signiﬁcance was considered at p-value < 0.05.
Table 2 Comparison of the 36-item short form health survey
(SF-36) between the rheumatoid arthritis (RA) patients and
control.
SF-36 domains
mean ± SD
RA
(n= 86)
Control
(n= 43)
p
PF 37.6 ± 8.5 88.1 ± 9.1 <0.0001
RP 33.7 ± 9.7 84.7 ± 12.5 <0.0001
BP 45.7 ± 6.1 89.1 ± 13.1 <0.0001
GH 41.3 ± 7.0 75.6 ± 10.5 <0.0001
VT 44.3 ± 8.9 70.8 ± 12.9 <0.0001
SF 37.9 ± 12.9 84.0 ± 12.5 <0.0001
RE 41.8 ± 11.9 89.2 ± 7.7 <0.0001
MH 41.4 ± 10.6 68.2 ± 10.6 <0.0001
PCS 34.4 ± 10.1 84.4 ± 7.8 <0.0001
MCS 42.6 ± 12 80.3 ± 7.6 <0.0001
RA: rheumatoid arthritis; PF: physical functioning; RP: role
limitations due to physical health problems; BP: bodily pain; GH:
general health perceptions; VT: vitality; SF: social functioning; RE:
role limitations attributable to emotional problems; MH: mental
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The present study included 86 RA patients predominantly
females (88.4%). Their mean age was 46.4 ± 11.7 years,
BMI 26.3 ± 4.6 and disease duration was 11.2 ± 7.2 years.
The mean age of the control group was 45.1 ± 13.5 years with
no signiﬁcant differences in the demographic data between the
RA patients and control (p> 0.05). The DAS28 showed that
the RA patients covered all grades of disease activity. Most of
the studied RA patients (97.7%) were on disease modifying
drugs; 10 (11.6%) on monotherapy and 74 (86.1) were on com-
bined therapy (Table 1).
Descriptive Statistics for the eight domains of SF36 in the
RA group showed low mean of all domains (<50) with the
role limitations due to physical health problems (RP) being
the lowest (33.7 ± 9.7) while body pains (BP) was the highest
(45.8 ± 6.1). Statistically signiﬁcant differences were found
between RA patients and control as regards the means of each
domain of the FS-36 (p< 0.0001) as illustrated in Table 2.Table 1 Demographic and clinical features of the studied
rheumatoid arthritis (RA) patients and control.
Feature RA (n= 86) Control (n= 43) p
Age (years) 46.4 ± 11.7 45.1 ± 13.5 0.59
BMI(kg/m2) 26.3 ± 4.6 26.4 ± 4.8 0.96
Disease duration (years) 11.2 ± 7.2 – –
Gender
Male 10 (11.6) 12 (27.9) 0.58
Female 76 (88.4) 31 (72.1)
Education
<High school 69 (80.2) 37 (86.04) 0.69
PHigh school 17 (19.8) 6 (13.95)
Working status
Nonworking 74 (86.04) 41 (95.3) 0.18
Working 12 (13.95) 2 (4.7)
Disease duration
65 years 28 (32.6)
>5 years 58 (67.4) – –
DAS-28
Remission/low activity 12 (13.95) – –
Moderate activity 42 (48.8)
High activity 32 (37.2)
RF positivity 42 (48.8) – –
EA manifestations 24 (27.9) – –
SCN 8 (9.3)
SS 16 (18.6)
Drug therapy
MTX 62 (72.1)
LEF 42 (48.8)
HQ 60 (69.8)
SSZ 6 (6.97)
Steroid 22 (25.6)
Monotherapy 10 (11.8)
Combined therapy 74 (86.1)
Results are presented as mean ± SD or n (%). RA: rheumatoid
arthritis; DD: disease duration; BMI: body mass index; DAS-28:
disease activity score 28; RF: rheumatoid factor; EA: extra-artic-
ular; SCN: subcutaneous nodule; SS: Sjo¨gren syndrome; MTX:
methotrexate; LEF: leﬂunomide; HCQ: hydroxychloroquine; SSZ:
sulfasalazine.
health; PCS: physical component summary; MCS: mental
component summary.Table 3 shows a comparison between SF-36 components
and the demographic and clinical parameters in RA patients.
Table 4 shows the correlation between SF-36 components
and some demographic and clinical parameters in RA patients.
Regarding the multiple linear regression analysis (Table 5),
both PCS and MCS signiﬁcantly intercepted together in mod-
els (p< 0.0001). The most signiﬁcant predictor for both com-
ponents was the disease duration (p< 0.0001).
4. Discussion
Rheumatoid arthritis (RA) is a chronic autoimmune disease
with a signiﬁcant impact on the QoL, both physical and mental
domains of wellbeing. In the present study, quality of life in
RA patients was studied using the SF36 questionnaire which
is the most widely used generic measure of health status.
There have been many previous studies of SF-36 proﬁles in
RA. Birrell et al. studied 86 RA patients attending specialist
clinics and found that impairment of health status was moder-
ate to marked by the SF-36, with signiﬁcant differences from
population norms and chronic disease states such as low back
pain. They concluded that it is a practical tool for use in
patients with RA [21]. In accordance with our results, in
another study on 26 Egyptian early RA patients from Sohag,
the QoL was impaired also using the SF-36 measure [22]. In
the present study, impairment of all the 8 domains of the
SF36 was found in the RA patients, where the score of each
domain was less than 50% of its maximum score. There is a
great deal of information suggesting that arthritis has a devas-
tating effect on HRQoL [23]. One large survey makes this
point clear where data from 32,322 adults in 11 US states indi-
cated that adults with arthritis report signiﬁcantly greater
HRQoL impairment compared to those without [24].
In our study, disease activity signiﬁcantly correlated with
both components of SF 36. Signiﬁcantly high PCS score
was found among RA patients with low DAS28 compared
to those with moderate and high DAS28 (p< 0.0001). This
Table 3 Comparison of means between SF-36 components
and demographic and clinical parameters in RA patients.
Parameters in RA patients
(N= 86) Mean ± SD (p-value)
SF-36 components
N PCS MCS
Education <High
school
69 32.4 ± 9.8 41.2 ± 12.1
PHigh
school
17 42.1 ± 7.3 48.2 ± 10.2
(<0.0001) (0.03)
Work status Non-
working
74 33.5 ± 10.3 41.7 ± 12.3
Working 12 39.5 ± 6.6 48.1 ± 8.5
(0.03) (0.04)
BMI Normal 30 35.3 ± 11.2 43.7 ± 11.6
Increased 56 33.8 ± 9.5 42.0 ± 12.3
(0.51) (0.36)
Disease duration 65 years 28 37.7 ± 11.6 46.1 ± 12.3
>5 years 58 32.7 ± 8.9 40.9 ± 11.7
(0.03) (0.11)
RF Negative 44 38.3 ± 9.6 41.9 ± 12.2
Positive 42 30.2 ± 8.9 43.3 ± 12.0
(<0.0001) (0.64)
Disease activity
(DAS28)
Remission/
low
12 46.2 ± 6.1 50.5 ± 8.2
Moderate 42 35.2 ± 8.3 40.9 ± 11.8
High 32 28.9 ± 9.4 41.8 ± 12.7
(<0.0001) (0.06)
HCQ Non users 26 34.6 ± 9.5 48.5 ± 11.3
Users 60 34.3 ± 10.4 40.0 ± 11.5
(0.83) (<0.0001)
Steroid Non users 64 34.3 ± 10.6 44.5 ± 12.3
Users 22 34.6 ± 8.6 37.0 ± 9.5
(0.93) (0.01)
PCS: physical component summary; MCS: mental component
summary; BMI: body mass index; RF: rheumatoid factor; DAS-28:
disease activity score 28; HCQ: hydroxychloroquine.
Table 4 Correlation between SF-36 components and some
demographic and clinical parameters in RA patients.
Parameters SF-36 components in RA patients (n= 86)
r (p) PCS MCS
Age 0.16 (0.07) 0.07 (0.39)
Education 0.17 (0.06) 0.1 (0.27)
Work status 0.02 (0.82) 0.03 (0.73)
BMI 0.07 (0.44) 0.05 (0.62)
Disease duration 0.3 (0.01) 0.32 (<0.0001)
RF 0.44 (<0.0001) 0.02 (0.88)
DAS-28 0.69 (<0.0001) 0.36 (<0.0001)
HCQ therapy 0.02 (0.84) 0.34 (<0.0001)
Steroid therapy 0.01 (0.94) 0.26 (0.02)
PCS: physical component summary; MCS: mental component
summary; BMI: body mass index; RF: rheumatoid factor; DAS-28:
disease activity score 28; HCQ: hydroxychloroquine.
Table 5 Quality of life predictors among rheumatoid arthritis
patients (n= 86).
B t p 95%CI for B
PCS predictors
Constant 56.4 10.7 <0.0001 45.8–66.9
Age 0.04 0.5 0.62 0.1 to 0.2
BMI 0.01 0.05 0.96 0.4 to 0.4
Disease
duration
0.3 3.03 <0.0001 0.6 to 0.1
RF 0.02 2.8 0.01 0.04 to
0.01
DAS-28 4.2 7.05 <0.0001 5.4 to
3.01
Model R2 = 0.5, F= 17.2, p< 0.0001
MCS predictors
Constant 54.8 6.7 <0.0001 38.5–71.04
Age 0.08 0.7 0.48 0.2 to 0.3
BMI 0.03 0.1 0.9 0.6 to 0.54
Disease
duration
0.6 3.4 <0.0001 0.9 to
0.24
RF 0.02 1.4 0.17 0.05 to 0.01
DAS-28 1.8 1.9 0.06 3.6 to 0.07
Model R2 = 0.2, F= 3.9, p< 0.0001
BMI: body mass index; RF: rheumatoid factor; DAS-28: disease
activity score 28.
68 R.M. Gamal et al.could be explained by the fact that disease activity score is
closely related to the extent of joint inﬂammation and
destruction. These ﬁndings were consistent with some studies;where disease activity has been shown to be correlated with
both physical and psychological domains of HRQoL
[25,26]. Nevertheless, other studies have demonstrated that
disease related variables are strong determinants of physical
disability, but not necessarily the mental health. [27]. It is
worth mentioning that in all of these studies, disease activity
has a stronger correlation with physical health than with
mental health.
A strong negative correlation was found between disease
duration and both mental and physical domains of the SF-
36, where greater impairment was reported with prolonged dis-
ease duration. This could be related to the increased prevalence
of depression among RA patients [28] and the ﬁndings that
lifetime mood depressive symptoms signiﬁcantly contribute
to impairment in HRQoL in RA patients [29]. In contrast,
longer disease duration was associated with improved MCS
in RA patients in a recent systematic review and meta-
analysis [23], with a suggested explanation that patients expe-
riencing symptoms for a longer duration may have a greater
level of acceptance of their condition than patients with recent
onset disease. Variation in the demographic and socioeco-
nomic characters of the studied populations could contribute
to this controversy.
Of additional interest, the statistically signiﬁcant negative
correlation between receiving HCQ or steroids and MCS
score. Psychiatric side effects with HCQ were reported in sev-
eral studies and included irritability, nervousness, emotional
changes, nightmares, and psychosis [30,31]. And a greater
bulk of papers had documented the psychiatric side effects
of glucocorticoids as a spectrum of psychiatric symptoms
ranging from subtle mood changes to memory deﬁcits to
frank psychosis that can occur at any time during treatment
[32,33].
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associated with both domains of SF-36, where higher educa-
tion level was associated with better QoL score. There is a clear
presumption in the literature that low literacy and numeracy
means health communication is poorly understood, leading
to inadequate self-management and perceptions of health
responsibility and inappropriate health care utilization [34].
Similarly, working RA patients showed better QoL scores both
physically and mentally compared to non-working patients.
This is supported by what had been reported in some studies
[35,36] that having a job and being married had signiﬁcant cor-
relation with improving some aspects in RA patients’ QoL. As
stated above, it might be expected that work provides social
status and income and might be valued for its social support
and social distraction. Citera et al. [37] found that unemployed
patients had higher DAS28, worse HAQ values, and less years
of formal education (p< 0.005 in all comparisons).
We found RF to correlate negatively with the physical but
not the mental domain of the SF-36. This is supported by a
study [38] which involved 245 RA patients and showed that
the decreased physical function was associated with the higher
levels of RF. A possible explanation could be that positive RF
titer has already been shown to be associated with the presence
of erosions, and the severity of RA. Some other studies found
no correlation between the RF and the QoL score and sug-
gested that disability and QoL assessment tools such as the
HAQ and the SF-36, may reﬂect the damage caused by RA
activity but behave independently of autoantibodies [39,40].
Multiple linear regression was constructed to detect the
predictor of low QoL in the studied RA group. It showed that
disease duration was the most important independent predict-
ing factor where it was related to impaired both physical and
mental components of SF 36.
This study has some limitations that should be considered
when interpreting its results. First, it was conducted in a ter-
tiary care center where more aggressive cases of RA would
be overrepresented. These results therefore do not reﬂect the
real status in the community. Second, the cross-sectional
design limits the analysis about the associated disease variables
with HRQoL and does not allow drawing ﬁnal conclusions
about the strengths of the cause–effect relationships. Third,
this was a single center study with limited sample size, so the
results could not be generalized to the RA patients in the com-
munity. Lastly, HRQoL of RA patients is inﬂuenced by sev-
eral more variables which were not measured in our study.
5. Conclusion
Despite the limitations discussed above, our study conﬁrms
that RA has a signiﬁcant effect on the health related quality
of life of patients. The disease duration was the most inﬂuenc-
ing factor on both the physical and mental function. Routine
assessment of the HRQoL in those patients is recommended
to detect and monitor the impact of the disease and its medica-
tions on different aspects. Longitudinal studies are needed to
examine how these quality of life measures, change over time
and respond to different management interventions.
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